Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori

Vonoprazan (VPZ) inhibits gastric acid secretion more potently than proton pump inhibitors. Recently, attention has been focused on the dual therapy with VPZ and amoxicillin (AMOX) for the eradication of H. pylori. The dual VPZ/AMOX therapy attains the sufficient eradication rate with lowering the risk of adverse events in comparison with the triple therapy and quadruple therapy. Therefore, the dual VPZ/AMOX therapy is considered a useful eradication regimen for H. pylori infection.

[1]  Chao-Yi Ge,et al.  A real‐world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin‐containing therapies , 2023, Helicobacter.

[2]  H. Kaneko,et al.  Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: A single‐arm, interventional study , 2022, JGH open : an open access journal of gastroenterology and hepatology.

[3]  Zheng Hua Zhu,et al.  Fourteen-day vonoprazan and low- or high-dose amoxicillin dual therapy for eradicating Helicobacter pylori infection: A prospective, open-labeled, randomized non-inferiority clinical study , 2023, Frontiers in Immunology.

[4]  Wenjie Li,et al.  Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy , 2022, The American journal of gastroenterology.

[5]  Yoshiyuki Watanabe,et al.  Clinical evaluation of a novel molecular diagnosis kit for detecting Helicobacter pylori and clarithromycin‐resistant using intragastric fluid , 2022, Helicobacter.

[6]  G. Teng,et al.  Eradication rate and safety of a “simplified rescue therapy”: 14‐day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real‐world, retrospective clinical study in China , 2022, Helicobacter.

[7]  F. Mégraud,et al.  Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the US and Europe: Randomized Clinical Trial. , 2022, Gastroenterology.

[8]  X. Shu,et al.  Optimization of vonoprazan‐amoxicillin dual therapy for eradicating Helicobacter pyloriinfection in China: A prospective, randomized clinical pilot study , 2022, Helicobacter.

[9]  F. Ali,et al.  Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial , 2022, Pakistan journal of medical sciences.

[10]  Xiaohui Yu,et al.  The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study , 2022, Annals of Translational Medicine.

[11]  T. Gotoda,et al.  Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan , 2020, Journal of Gastroenterology.

[12]  Shuanghu Wang,et al.  Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo , 2020, Frontiers in Pharmacology.

[13]  H. Miyajima,et al.  Influence of clarithromycin on the bactericidal effect of amoxicillin in patients infected with clarithromycin-resistant strains of H. pylori , 2020, Gut.

[14]  T. Gotoda,et al.  Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan , 2020, Gut.

[15]  H. Miyajima,et al.  Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori , 2019, Digestion.

[16]  Keng-Liang Wu,et al.  A 14 day esomeprazole- and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-Helicobacter pylori treatment in Taiwan: a prospective randomized trial. , 2019, The Journal of antimicrobial chemotherapy.

[17]  T. Shim,et al.  Risk for cardiovascular disease in patients with nontuberculous mycobacteria treated with macrolide. , 2018, Journal of thoracic disease.

[18]  H. Miyajima,et al.  Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype , 2018, Clinical pharmacology and therapeutics.

[19]  S. Maeda,et al.  Vonoprazan‐ vs proton‐pump inhibitor‐based first‐line 7‐day triple therapy for clarithromycin‐susceptible Helicobacter pylori: A multicenter, prospective, randomized trial , 2018, Helicobacter.

[20]  R. Hunt,et al.  Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report , 2016, Gut.

[21]  H. Miyajima,et al.  Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype , 2016, Alimentary pharmacology & therapeutics.

[22]  K. Murakami,et al.  Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study , 2016, Gut.

[23]  T. Fasciana,et al.  Resistance to clarithromycin and genotypes in Helicobacter pylori strains isolated in Sicily. , 2015, Journal of medical microbiology.

[24]  Y. Sakurai,et al.  Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over study , 2015, Alimentary pharmacology & therapeutics.

[25]  D. Graham,et al.  High‐Dose Extended‐Release Lansoprazole (Dexlansoprazole) and Amoxicillin Dual Therapy for Helicobacter pylori Infections , 2014, Helicobacter.

[26]  G. Sachs,et al.  The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin , 2012, Alimentary pharmacology & therapeutics.

[27]  T. Hibi,et al.  Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction. , 2012, World journal of gastroenterology.

[28]  L. Drago,et al.  Comparative evaluation of synergy of combinations of beta-lactams with fluoroquinolones or a macrolide in Streptococcus pneumoniae. , 2011, The Journal of antimicrobial chemotherapy.

[29]  D. Graham,et al.  Pharmacologic aspects of eradication therapy for Helicobacter pylori Infection. , 2010, Gastroenterology clinics of North America.

[30]  T. Furuta,et al.  The dual therapy with 4 times daily dosing of rabeprazole and amoxicillin as the 3rd rescue regimen for eradication of H. pylori. , 2010, Hepato-gastroenterology.

[31]  T. Joh,et al.  Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin , 2010, Journal of clinical biochemistry and nutrition.

[32]  M. Stolte,et al.  One‐Week Once‐Daily Triple Therapy with Esomeprazole, Moxifloxacin, and Rifabutin for Eradication of Persistent Helicobacter pylori Resistant to Both Metronidazole and Clarithromycin , 2008, Helicobacter.

[33]  T. Ishizaki,et al.  Evidence that the Degree and Duration of Acid Suppression are Related to Helicobacter pylori Eradication by Triple Therapy , 2007, Helicobacter.

[34]  K. Ohashi,et al.  Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy , 2007, European Journal of Clinical Pharmacology.

[35]  M. Stolte,et al.  Randomized trial of rifabutin‐based triple therapy and high‐dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin , 2006, Alimentary pharmacology & therapeutics.

[36]  M. Huang,et al.  Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs , 2005, Clinical pharmacokinetics.

[37]  K. Ohashi,et al.  Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status , 2004, Clinical pharmacology and therapeutics.

[38]  K. Ohashi,et al.  High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. , 2003, Hepato-gastroenterology.

[39]  M. Vieth,et al.  A Prospective, Randomized Study of Quadruple Therapy and High‐Dose Dual Therapy for Treatment of Helicobacter Pylori Resistant to Both Metronidazole and Clarithromycin , 2003, Helicobacter.

[40]  H. Isomoto,et al.  High‐dose rabeprazole–amoxicillin versus rabeprazole–amoxicillin–metronidazole as second‐line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection , 2003, Alimentary pharmacology & therapeutics.

[41]  H. Kutsumi,et al.  Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1‐week regimen of proton pump inhibitor, amoxicillin and clarithromycin , 2003, Alimentary pharmacology & therapeutics.

[42]  K. Murakami,et al.  Eradication rates of clarithromycin‐resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin , 2002, Alimentary pharmacology & therapeutics.

[43]  K. Yokota,et al.  A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism , 2001, Journal of gastroenterology and hepatology.

[44]  H. Sugimura,et al.  Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. , 2001, Pharmacogenetics.

[45]  H. Sugimura,et al.  Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin , 2001 .

[46]  M. Asaka,et al.  High‐dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin , 2000, Alimentary pharmacology & therapeutics.

[47]  Xiao,et al.  Comparison of lansoprazole‐based triple and dual therapy for treatment of Helicobacter pylori‐related duodenal ulcer: an Asian multicentre double‐blind randomized placebo controlled study , 2000, Alimentary pharmacology & therapeutics.

[48]  Kyoichi Ohashi,et al.  Effect of Genetic Differences in Omeprazole Metabolism on Cure Rates for Helicobacter pylori Infection and Peptic Ulcer , 1998, Annals of Internal Medicine.

[49]  J. Freston,et al.  Triple Versus Dual Therapy for Eradicating Helicobacter pylori and Preventing Ulcer Recurrence: A Randomized, Double-Blind, Multicenter Study of Lansoprazole, Clarithromycin, and/or Amoxicillin in Different Dosing Regimens , 1998, American Journal of Gastroenterology.

[50]  S. Tanabe,et al.  A prospective randomized study of amoxycillin and omeprazole with and without metronidazole in the eradication treatment of Helicobacter pylori , 1998, Journal of gastroenterology and hepatology.

[51]  W. Craig.  Choosing an antibiotic on the basis of pharmacodynamics. , 1998, Ear, nose, & throat journal.

[52]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[53]  M. Copeman,et al.  Two omeprazole‐based Helicobacter pylori eradication regimens for the treatment of duodenal ulcer disease in general practice , 1997, Alimentary pharmacology & therapeutics.

[54]  C. Bate,et al.  Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double‐blind, randomized trial , 1995, Alimentary pharmacology & therapeutics.

[55]  S. Miehlke,et al.  Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. , 1995, Gastroenterology.

[56]  W. Craig.  Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. , 1995, Diagnostic microbiology and infectious disease.

[57]  M. Stolte,et al.  An increasing dose of omeprazole combined with amoxicillin improves the cure of Helicobacter pylori infection , 1995 .